Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332451 | 0.90 | TLR7 (0.43) | MAPTADORA2BADORA2ATLR7ADORA1 | |
| SCHEMBL1333024 | 0.89 | TLR7 (0.42) | MAPTADORA2BADORA2ATLR7ADORA1 | |
| SCHEMBL4327693 | 0.88 | ADORA1 (0.44) | MAPTADORA2BADORA2ATLR7ADORA1 | |
| SCHEMBL1334537 | 0.83 | ADORA2B (0.42) | MAPTADORA2BADORA2AADORA1TP53 | |
| SCHEMBL5834314 | 0.81 | ADORA1 (0.42) | MAPTADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1334451 | 0.79 | ADORA1 (0.47) | ADORA2BADORA2AADORA1ADORA3KMT2A | |
| SCHEMBL4174562 | 0.77 | TLR7 (0.44) | MAPTADORA2BADORA2ATLR7ADORA1 | |
| SCHEMBL4165169 | 0.77 | ADORA1 (0.48) | MAPTADORA2BADORA2ATLR7ADORA1 | |
| SCHEMBL1333414 | 0.76 | ADORA1 (0.48) | MAPTADORA2BADORA2ATLR7ADORA1 | |
| SCHEMBL4165166 | 0.75 | TLR7 (0.42) | MAPTADORA2BADORA2ATLR7ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110282031-A1 | A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES | WILSON CONSTANCE N (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282031-A1 | A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES | ADORA1, ADORA3, ADORA2A | MAPT 4267/4885ADORA2B 4/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.